T cell receptor of acute myelogenous leukemia epitope peptide DNMT3A-R882S and application thereof

By developing the T cell receptor of HLA-A11 restriction DNMT3A-R882S epitope peptide, TCR-T cells were constructed, and the problem of difficulty in treating acute myeloid leukemia and insufficient HLA-A11 patients was solved, and the DNMT3A-R882S mutant antigen was achieved The specific identification and killing of the Chinese population provides a new immunotherapy regimen.

CN118930636AActive Publication Date: 2024-11-12INST OF MICROBIOLOGY CHINESE ACAD OF SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410959136.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-12
Estimated Expiration
2044-07-17

AI Technical Summary

Technical Problem

The treatment of acute myeloid leukemia is difficult, and the existing treatment methods are insufficient for HLA-A11 restrictive patients, especially in the Chinese population.

Method used

Develop T cell receptors that identify HLA-A11 restriction DNMT3A-R882S epitope peptides, including specific alpha and beta chain variant regions, obtain T cell receptors by connecting the alpha and beta chains by connecting the peptides, and through biological Materials such as nucleic acid molecules, expression cassettes and recombinant vectors are biologically expressed, and TCR-T cells are constructed to target DNMT3A-R882S mutant antigens.

Benefits of technology

Successfully constructed TCR-T cells specific for DNMT3A-R882S, which can verify their killing ability and specificity to target cells in vitro, and provide a novel immunotherapy regimen for HLA-A11 restricted acute myeloid leukemia, which is particularly applicable. For Chinese people.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004949778970000011
    Figure HDA0004949778970000011
  • Figure HDA0004949778970000012
    Figure HDA0004949778970000012
  • Figure HDA0004949778970000021
    Figure HDA0004949778970000021
Patent Text Reader

Abstract

The invention discloses a T cell receptor of an acute myelogenous leukemia epitope peptide DNMT3A-R882S and an application of the T cell receptor. The T cell receptor disclosed by the invention contains an alpha chain and a beta chain, and variable region sequences of the alpha chain and the beta chain are 21st-110th sites of SEQ ID No.2 and 20th-114 sites of SEQ ID No.4 respectively. Experiments prove that the T cell receptor disclosed by the invention can specifically recognize and be combined with a DNMT3A-R882S epitope peptide / HLA-A11 compound; meanwhile, it is verified in vitro that the TCR transgenic positive human CD8 cell (TCR-T) has the DNMT3A-R882S epitope peptide dependent human target cell killing capacity. The T cell receptor of the HLA-A11 restrictive DNMT3A-R882S epitope peptide disclosed by the invention has an important application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a T cell receptor of an acute myeloid leukemia epitope peptide DNMT3A-R882S and application thereof in the field of biomedicine. Background Art

[0002] Leukemia is a blood disease caused by the proliferation of malignant clones of hematopoietic stem cells. Its clinical manifestations include an abnormal increase in the number of white blood cells in the patient's blood and bone marrow, which leads to severe damage to the hematopoietic function and affects all tissues and organs throughout the body, seriously endangering human health. Therefore, it is also called "blood cancer". Among them, acute leukemia (AL) has the highest incidence rate among all leukemias. Its diseased cells are generally hematopoietic cells in the early differentiation stage, and the onset is rapid, making clinical treatment more difficult. Acute leukemia is divided into acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) according to the different affected cells.

[0003] AML is a highly heterogeneous clonal disease, and its onset is closely related to gene mutations in hematopoietic precursor cells. Studies have shown that the common mutated genes in AML patients in clinical practice mainly involve functional categories such as signal activation, myeloid transcription factors, DNA methylation, chromatin shearing, and nucleolar phosphatase localization. Mutations in these genes can lead to disorders in physiological processes such as normal cell transcription, protein kinases, and epigenetic modifications, thereby leading to abnormal cell proliferation and hematopoietic function. Clinical studies have shown that the occurrence and recurrence of AML are often accompanied by a series of gene mutations. Some genes with hotspot mutations have a higher frequency of occurrence, such as NPM1 (25%-35%), FLT3 (20%-27%), DNMT3A (18%-22%), TET2 (7%-22%), TP53 (8%-15%), etc. The significance of gene mutations in AML is very important for disease progression, the development of effective therapies, and prognosis after treatment. In addition, some hotspot mutations may also indicate the existence of new targets, which may provide new ideas for clinical immunotherapy of AML.

[0004] The DNMT3A (DNAmethyltransferase 3alpha) gene encodes a DNA methyltransferase that can mediate de novo methylation and can directly methylate target DNA fragments (such as promoters, etc.), thereby affecting gene expression and genomic stability. Genetic variations in the DNMT3A promoter or coding region have been shown to be associated with gastric cancer and AML, especially the R882 residue in DNMT3A is one of the most frequently mutated sites in AML patients.

[0005] Antigens produced by gene mutations cannot be expressed on the surface of ALL cells and targeted by CAR-T, but can be processed by MHC molecules and presented on the cell surface by CD8 + T cell recognition, so specific gene mutations can be used as specific targets for AML TCR-T therapy. Therefore, using TCR-T instead of CAR-T to target gene mutation antigens for immunotherapy of AML may be a very effective new method.

[0006] Human leukocyte antigen (HLA) is the MHC of humans and an important genetic marker of humans. HLA gene is the most complex genetic complex known to humans. It is highly polymorphic and plays an important role in immune regulation. Up to now, there are more than 20,000 known HLA alleles, including HLA class I molecules (HLA-A / B / C) and HLA class II molecules (HLA-DR / DQ / DP), etc. They are mixed and specifically expressed on the surface of human cells, making HLA polymorphism rich among individuals. Studies have shown that in the Chinese population, the HLA-A3 superfamily (A11, A33, A31, A68) accounts for the largest proportion of all HLA typing, about 52.7%, among which the HLA-A11 subtype has the highest frequency. The existing reported research on therapeutic T cells is mainly limited to the research on HLA-A2 population, while the attention to other HLA populations is obviously insufficient. Therefore, TCR-T research targeting the HLA-A11-restricted DNMT3A-R882S mutation site is of great significance for immunotherapy in the Chinese population.

[0007] In summary, immunotherapy for acute myeloid leukemia, especially TCR-T therapy, has important advantages in improving the current status of clinical treatment of acute leukemia, increasing clinical remission rate, and prolonging patient survival, and is a promising future treatment direction. Combined with the MHC restriction of TCR-T and the HLA preference of the Chinese population, the development of HLA-A11-restricted TCR-T specific for ALL can provide a new solution for the treatment of HLA-A11-restricted acute myeloid leukemia, which is mainly in the Chinese population. Summary of the invention

[0008] The technical problem to be solved by the present invention is how to treat acute myeloid leukemia.

[0009] In order to solve the above technical problems, the present invention first provides a T cell receptor that recognizes an HLA-A11 restricted DNMT3A-R882S epitope peptide, which comprises an α chain and a β chain, wherein the α chain comprises complementary determining regions CDR1α, CDR2α and CDR3α, and CDR1α is a1) or a2):

[0010] a1) the polypeptide shown at positions 47 to 52 of SEQ ID No. 2;

[0011] a2) a T cell receptor alpha chain complementary determining region having more than 75% identity with a1) obtained by substitution and / or deletion and / or addition of one or several amino acid residues (such as 3, 2 or 1 amino acid residues);

[0012] CDR2α is a3) or a4):

[0013] a3) the polypeptide shown at positions 70-75 of SEQ ID No.2;

[0014] a4) a T cell receptor alpha chain complementary determining region having more than 75% identity with a3) obtained by substitution and / or deletion and / or addition of one or several amino acid residues (such as 3, 2 or 1 amino acid residues) in a3);

[0015] CDR3α is a5) or a6):

[0016] a5) the polypeptide shown at positions 110-118 of SEQ ID No. 2;

[0017] a6) a T cell receptor alpha chain complementary determining region having more than 75% identity with a5) obtained by substitution and / or deletion and / or addition of one or several amino acid residues (such as 3, 2 or 1 amino acid residues);

[0018] The β chain contains complementarity determining regions CDR1β, CDR2β and CDR3β, and CDR1β is b1) or b2):

[0019] b1) the polypeptide shown at positions 46 to 50 of SEQ ID No. 4;

[0020] b2) a T cell receptor alpha chain complementary determining region having more than 75% identity with b1) obtained by substitution and / or deletion and / or addition of one or several amino acid residues (such as 3, 2 or 1 amino acid residues);

[0021] CDR2β is b3) or b4):

[0022] b3) the polypeptide shown at positions 68-73 of SEQ ID No. 4;

[0023] b4) a T cell receptor alpha chain complementary determining region having more than 75% identity with b3) obtained by substitution and / or deletion and / or addition of one or several amino acid residues (such as 3, 2 or 1 amino acid residues) in b3);

[0024] CDR3β is b5) or b6):

[0025] b5) the polypeptide shown at positions 111-122 of SEQ ID No. 4;

[0026] b6) a T cell receptor alpha chain complementary determining region having more than 75% identity with b5) obtained by replacing and / or deleting and / or adding one or more amino acid residues (such as 3, 2 or 1 amino acid residues) in b5).

[0027] In the above T cell receptor, the variable region of the α chain may be a7) or a8):

[0028] a7) the polypeptide shown at positions 21 to 110 of SEQ ID No. 2;

[0029] a8) a T cell receptor alpha chain variable region having more than 75% identity with a7) obtained by replacing and / or deleting and / or adding one or more amino acid residues (such as 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid residues) in a7);

[0030] The variable region of the β chain may be b7) or b8):

[0031] b7) shown in positions 20-114 of SEQ ID No. 4;

[0032] b8) b7) is obtained by replacing and / or deleting and / or adding one or several amino acid residues (such as 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid residues) to obtain a T cell receptor α chain variable region that has more than 75% identity with b7).

[0033] In the above-mentioned T cell receptor, the α chain and the β chain may comprise the constant region of mouse, human or humanized T cell receptor.

[0034] Specifically, the α chain may be a9) or a10):

[0035] a9) the polypeptide shown in SEQ ID No.2;

[0036] a10) a9) obtained by substitution and / or deletion and / or addition of one or more amino acid residues (e.g., 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid residue) to obtain a T cell receptor alpha chain having more than 75% identity with a9);

[0037] The beta chain is b9) or b10):

[0038] b9) the polypeptide shown in SEQ ID No.4;

[0039] b10) b9) is obtained by replacing and / or deleting and / or adding one or several amino acid residues (such as 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid residues) to obtain a T cell receptor β chain with more than 75% identity with b9).

[0040] In the above-mentioned T cell receptor, 75% or more identity may be 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity.

[0041] The α chain and β chain of the above-mentioned T cell receptor can be artificially synthesized, or their encoding genes can be synthesized first and then obtained by biological expression.

[0042] The T cell receptor may be composed of the α chain and the β chain, or may be obtained by connecting the α chain and the β chain. In one embodiment of the present invention, the T cell receptor is obtained by connecting the α chain and the β chain via a connecting peptide (such as a P2A self-cleaving polypeptide).

[0043] The present invention also provides the T cell receptor-related biological material, which is any one of the following C1) to C5):

[0044] C1) a nucleic acid molecule encoding the T cell receptor;

[0045] C2) an expression cassette containing the nucleic acid molecule described in C1);

[0046] C3) a recombinant vector containing the nucleic acid molecule described in C1), or a recombinant vector containing the expression cassette described in C2);

[0047] C4) a recombinant microorganism containing the nucleic acid molecule described in C1), or a recombinant microorganism containing the expression cassette described in C2), or a recombinant microorganism containing the recombinant vector described in C3);

[0048] C5) A cell, tissue or organ containing the nucleic acid molecule described in C1), or a cell, tissue or organ containing the expression cassette described in C2).

[0049] In the above-mentioned biological material, the nucleic acid molecule in C1) may be a nucleic acid molecule encoding the α chain and the β chain.

[0050] Specifically, in the α chain, the nucleic acid molecule encoding CDR1α may be a DNA molecule shown in positions 139-156 of SEQ ID No.1, or a DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85%, more than 80%, or more than 75% identity thereto and encodes the same amino acid residue sequence, the nucleic acid molecule encoding CDR2α is a DNA molecule shown in positions 208-225 of SEQ ID No.1, or a DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85%, more than 80%, or more than 75% identity thereto and encodes the same amino acid residue sequence, and the nucleic acid molecule encoding CDR3α is a DNA molecule shown in positions 328-354 of SEQ ID No.1, or a DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85%, more than 80%, or more than 75% identity thereto and encodes the same amino acid residue sequence.

[0051] Furthermore, the nucleic acid molecule encoding the variable region of the α chain may be a DNA molecule shown at positions 61-330 of SEQ ID No. 1, or a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity thereto and encoding the same amino acid residue sequence.

[0052] Furthermore, the nucleic acid molecule encoding the α chain may be a DNA molecule shown in SEQ ID No. 1 or a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity thereto and encoding the same amino acid residue sequence.

[0053] In the β chain, the nucleic acid molecule encoding CDR1β may be a DNA molecule shown in positions 136-150 of SEQ ID No.3, or a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity thereto and encoding the same amino acid residue sequence; the nucleic acid molecule encoding CDR2β is a DNA molecule shown in positions 202-219 of SEQ ID No.3, or a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity thereto and encoding the same amino acid residue sequence; the nucleic acid molecule encoding CDR3β is a DNA molecule shown in positions 331-366 of SEQ ID No.3, or a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity thereto and encoding the same amino acid residue sequence.

[0054] Furthermore, the nucleic acid molecule encoding the variable region of the β chain may be a DNA molecule shown at positions 58-342 of SEQ ID No. 3, or a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity thereto and encoding the same amino acid residue sequence.

[0055] Furthermore, the nucleic acid molecule encoding the β chain may be a DNA molecule shown in SEQ ID No. 3 or a DNA molecule having 99% or more, 95% or more, 90% or more, 85% or more, 80% or more, or 75% or more identity thereto and encoding the same amino acid residue sequence.

[0056] The term "identity" as used herein refers to sequence similarity to a natural nucleic acid sequence. "Identity" includes nucleotide sequences that have 75% or more, or 85% or more, or 90% or more, or 95% or more identity to the nucleotide sequence encoding the α chain, the β chain, or its functional fragment of the present invention. Identity can be evaluated by the naked eye or by computer software. Using computer software, the identity between two or more sequences can be expressed as a percentage (%), which can be used to evaluate the identity between related sequences.

[0057] In the above biological materials, the expression cassette containing the nucleic acid molecule encoding the T cell receptor (T cell receptor gene expression cassette) described in B2) refers to a DNA capable of expressing the T cell receptor in a host cell, and the DNA may include not only a promoter for initiating transcription of the T cell receptor gene, but also a terminator for terminating transcription of the T cell receptor gene. Furthermore, the expression cassette may also include an enhancer sequence.

[0058] Existing expression vectors can be used to construct a recombinant vector containing the T cell receptor gene expression cassette.

[0059] In the above biological materials, the vector may be a plasmid, cosmid, phage or virus vector, such as pCDH-MSCV-MCS-2A-GFP (System Biosciences, No.: CD731B-1).

[0060] The recombinant vector is a recombinant plasmid obtained by inserting a nucleic acid molecule encoding the α chain of the T cell receptor and a nucleic acid molecule encoding the β chain of the T cell receptor between the multiple cloning sites (such as EcoRI and BamHI) of the plasmid pCDH-MSCV-MCS-2A-GFP (System Biosciences, number: CD731B-1).

[0061] In one embodiment of the present invention, the recombinant lentiviral packaging vector may be a recombinant plasmid pCDH-MSCV-TCR-GFP. The recombinant plasmid pCDH-MSCV-TCR-GFP is a recombinant plasmid obtained by replacing the small DNA fragment between the restriction endonucleases EcoRI and BamHI of the lentiviral packaging vector pCDH-MSCV-MCS-2A-GFP with a TCRDNA fragment with a nucleotide sequence as shown in SEQ ID No.5, while other sequences remain unchanged. In SEQ ID No.5, positions 1 to 795 are the complete coding gene of the α chain, positions 796 to 861 are the coding gene of the P2A self-cleaving polypeptide, and positions 862 to 1776 are the complete coding gene of the β chain.

[0062] In the above biological materials, the microorganism can be yeast, bacteria, algae or fungi.

[0063] Among the above-mentioned biological materials, the transgenic animal cell lines, transgenic animal tissues and transgenic animal organs do not include reproductive materials.

[0064] The cell line can be a T cell line or a Jurkat cell. The T cell can specifically be a human T cell or a mouse T cell.

[0065] The present invention also provides a pharmaceutical composition comprising the T cell receptor or the biological material.

[0066] The pharmaceutical composition may further contain a DNMT3A-R882S polypeptide.

[0067] The active ingredient of the pharmaceutical composition may be the T cell receptor or the biological material, or a combination of the T cell receptor or the biological material and the DNMT3A-R882S polypeptide.

[0068] The DNMT3A-R882S polypeptide may be shown as SEQ ID No.7.

[0069] The pharmaceutical composition may further contain a pharmaceutically acceptable carrier.

[0070] Any of the following applications of the T cell receptor, the biomaterial, or the pharmaceutical composition also falls within the protection scope of the present invention:

[0071] X1) treatment and / or prevention of blood disorders;

[0072] X2) preparation of products for the treatment and / or prevention of blood disorders;

[0073] X3) Treatment and / or prevention of acute leukemia;

[0074] X4) Preparation of products for the treatment and / or prevention of acute leukemia;

[0075] X5) Treatment and / or prevention of acute myeloid leukemia;

[0076] X6) Preparation of products for the treatment and / or prevention of acute myeloid leukemia;

[0077] X7) treating and / or preventing diseases caused by the R882S mutation of DNMT3A;

[0078] X8) Prepare products for treating and / or preventing diseases caused by the R882S mutation of DNMT3A.

[0079] X9) treating and / or preventing DNMT3A-R882S-positive acute myeloid leukemia;

[0080] X10) preparing a product for treating and / or preventing DNMT3A-R882S-positive acute myeloid leukemia;

[0081] X11) killing target cells expressing DNMT3A-R882S epitope peptide in vivo or in vitro;

[0082] X12) preparing products for killing target cells in vivo or in vitro;

[0083] X13) Elimination of DNMT3A-R882S positive cells;

[0084] X14) preparing a product for eliminating DNMT3A-R882S positive cells;

[0085] X15) preparing cytotoxic cytokines IFN-γ and / or TNF-α.

[0086] Wherein, the product may be a medicine.

[0087] The use of DNMT3A-R882S polypeptide in the preparation of T cell receptors for acute myeloid leukemia epitope peptides also falls within the protection scope of the present invention.

[0088] The T cell receptor in the present invention may be an isolated or purified T cell receptor (TCR).

[0089] After a large number of experiments, the inventors of the present invention separated and identified a pair of DNMT3A-R882S-specific TCR sequences, successfully constructed corresponding TCR-T cells, and determined that this pair of TCR sequences specifically recognized and bound the DNMT3A-R882S epitope peptide / HLA-A11 complex; at the same time, in vitro verification of TCR transgenic positive human CD8 cells (TCR-T) with DNMT3A-R882S epitope peptide-dependent killing of human target cells. The T cell receptor for the HLA-A11-restricted DNMT3A-R882S epitope peptide provided by the present invention has important application value.

[0090] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way. BRIEF DESCRIPTION OF THE DRAWINGS

[0091] Figure 1 CTL detection after mice were immunized with DNMT3A-R882S peptide. PMA stimulation was used as control.

[0092] Figure 2 CD8 cells were sorted for DNMT3A-R882S specificity.

[0093] Figure 3 The staining results of Jurkat cells expressing DNMT3A-R882S-specific TCR.

[0094] Figure 4 Preparation of TCR-T cells by mRNA electroporation of human primary T cells.

[0095] Figure 5 This is the result that DNMT3A-R882S-specific Human TCR-T cells have the function of killing target cells in vitro. ** indicates significant p < 0.01, **** indicates significant p < 0.0001.

[0096] Figure 6 These are the results of cytokine release detection when Human TCR-T cells kill target cells in vitro. DETAILED DESCRIPTION

[0097] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are carried out according to the techniques or conditions described in the literature in the art or according to the product instructions. The materials, reagents, instruments, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources. The quantitative tests in the following examples were all repeated at least three times, and the results were averaged. In the following examples, unless otherwise specified, the first position of each nucleotide sequence in the sequence table is the 5' terminal nucleotide of the corresponding DNA / RNA, and the last position is the 3' terminal nucleotide of the corresponding DNA / RNA.

[0098] HLA-A11 / hTAP-LMP transgenic mice are recorded in the following document: "Man Huang, Wei Zhang, Jie Guo, Xundong Wei, Krung Phiwpan, Jianhua Zhang, Xuyu Zhou. Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation. Scientific Report. 2016, doi: 10.1038 / srep33612". The public can obtain the biological material from the applicant. The biological material is only used to repeat the relevant experiments of the present invention and cannot be used for other purposes.

[0099] Example 1. Acquisition and application of TCR-T cells

[0100] 1. Screening of HLA-A11-restricted DNMT3A-R882S epitope peptide-specific TCR sequences using HLA-A11 / hTAP-LMP transgenic mice

[0101] 1. DNMT3A-R882S epitope peptide immunoassay

[0102] (1) Mix and emulsify 100 μL of PBS buffer containing 50 μg of DNMT3A-R882S peptide and 100 μL of IFA; then inject subcutaneously into HLA-A11 / hTAP-LMP transgenic mice at multiple points. The HLA-A11 / hTAP-LMP transgenic mice will induce a primary CTL immune response against the DNMT3A-R882S epitope.

[0103] (2) Seven days after completing step (1), peripheral blood was collected from the immunized mice, red blood cells were lysed, and then the cells were stimulated with the polypeptide DNMT3A-R882S for 4 h, followed by intracellular IFNg staining.

[0104] At the same time, peripheral blood of non-immunized HLA-A11 / hTAP-LMP transgenic mice was obtained, and the red blood cells were lysed and stimulated with the peptide DNMT3A-R882S for 4 h, followed by intracellular IFNg staining as a control.

[0105] Test results see Figure 1 (The control mice were non-immunized HLA-A11 / hTAP-LMP transgenic mice). The test results showed that after immunization with DNMT3A-R882S peptide, mice were able to stimulate specific CD8 + T cells generate CTL responses and release IFN-γ.

[0106] 2. Take the IFN-γ-immunized mice obtained in step 1 and perform Tetramer DNMT3A-R882S-positive CD8 + T cells were sorted.

[0107] Tetramer DNMT3A-R882S positive CD8 + The results of T cell sorting efficiency and purity test are shown in Figure 2 .

[0108] 3. TCR gene fragment amplification and sequencing

[0109] Extract Tetramer DNMT3A-R882S positive CD8 + The RNA of T cells was then reverse transcribed to obtain the cDNA of Tetramer DNMT3A-R882S positive CD8+ T cells. + Using the cDNA of T cells as a template, TCRα chain fragments and TCRβ chain fragments were amplified using conserved region primers. The amplified TCRα chain fragments and β chain fragments were connected to the T vector, which was then sequenced to isolate a pair of TCRs.

[0110] The coding gene of the α chain variable region is shown in positions 61 to 330 of SEQ ID No. 1, wherein positions 139 to 156, positions 208 to 225, and positions 328 to 354 in SEQ ID No. 1 are coding genes for three CDRs, respectively;

[0111] The amino acid sequence of the α chain variable region is shown in positions 21 to 110 of SEQ ID No. 2, wherein positions 47 to 52, 70 to 75 and 110 to 118 in SEQ ID No. 2 are three complementary determining regions, respectively.

[0112] The coding gene of the beta chain variable region is shown in positions 58-342 of SEQ ID No. 3, wherein positions 136-150, 202-219 and 331-366 of SEQ ID No. 3 are coding genes of three CDRs respectively;

[0113] The amino acid sequence of the β chain variable region is shown in positions 20-114 of SEQ ID No. 4, wherein positions 46-50, 68-73 and 111-122 in SEQ ID No. 4 are three complementary determining regions, respectively.

[0114] This pair of TCR receptors consisting of the α chain sequence shown in SEQ ID No. 2 and the β chain sequence shown in SEQ ID No. 4 may have high affinity for the HLA-A11 restricted CTL epitope DNMT3A-R882S and come from the same T cell clone.

[0115] II. Acquisition and identification of Jurkat cells expressing TCR

[0116] 1. Based on the sequences of the α chain variable region and the β chain variable region obtained in step 1, and referring to the mouse genome α chain and the α chain constant region sequences on NCBI, the complete coding genes of the HLA-A11 restricted DNMT3A-R882S specific TCR receptor α chain and β chain were obtained and artificially synthesized.

[0117] The complete coding gene of the α chain is shown in SEQ ID No.1, encoding the α chain shown in SEQ ID No.2.

[0118] The complete coding gene of the β chain is shown in SEQ ID No.3, encoding the β chain shown in SEQ ID No.4.

[0119] 2. Replace the DNA fragment between the restriction endonuclease EcoRI and BamHI recognition sequences of the plasmid pCDH-MSCV-MCS-2A-GFP (System Biosciences, No.: CD731B-1) with the TCR DNA fragment with the nucleotide sequence as shown in SEQ ID No.5, and keep other sequences unchanged to obtain the recombinant plasmid pCDH-MSCV-TCR-GFP. In SEQ ID No.5, positions 1 to 795 are the complete coding gene of the α chain, positions 796 to 861 are the coding gene of the P2A self-cleavage polypeptide, and positions 862 to 1776 are the complete coding gene of the β chain.

[0120] 3. Culture Jurkat cells to a number of 2×10 7The cells were collected and washed twice with 1640 medium without antibiotics. After the last wash, the cells were resuspended to 5×10 7 / mL, transfer the above cells into 400 μL / portion into an electroporation cup (BIO-RAD, catalog number: 165-2088), add 40 μg of recombinant plasmid pCDH-MSCV-TCR-GFP, mix well, and place the electroporation cup into an electroporator (BIO-RAD, Gene Pulser Xcell TM ), voltage 250V, capacitance 950μF, and then let it stand for 15min. Filter the cells with a sterile 200-mesh nylon filter and move them to a 6-well plate. After 12h, 1640 medium containing antibiotics can be added for culture. The expression of the target gene can be detected within 12-48h. The recombinant plasmid pCDH-MSCV-TCR-GFP was introduced into Jurkat cells to obtain Jurkat cells expressing TCR.

[0121] 4. Tetramer (HLA-A11 / DNMT3A-R882S) was used to stain the TCR-expressing Jurkat obtained in step 3. The reagents used were Anti-mouse TCR beta (H57-597, Invitrogen), HLA-A*11:01 Monomer UVX (Biolegend), and APC Streptavidin (eBioscience). The negative control was the untreated cell group. The electrotransfected cells were incubated with wild-type Tetramer (loaded with non-mutated peptide) and DNMT3A-R882S Tetramer (loaded with mutant peptide).

[0122] The staining results are shown in Figure 3 The results showed that this TCR had a strong affinity for the HLA-A11-restricted DNMT3A-R882S epitope.

[0123] 3. Human TCR-T cells have the function of killing target cells in vitro

[0124] In order to verify the ability of Human TCR-T to specifically kill target cells in vitro, an in vitro killing experiment was performed. The specific steps are as follows:

[0125] 1. Isolation of human peripheral T lymphocytes

[0126] (1) Draw 5 mL of peripheral venous blood from a human.

[0127] (2) After completing step (1), take a centrifuge tube (size: 50 mL), add 5 mL of peripheral blood and 5 mL of PBS buffer, and mix thoroughly.

[0128] (3) After completing step (2), add 5 mL of human peripheral blood lymphocyte separation solution (Tianjin Haoyang Biological Products Technology Co., Ltd., catalog number: LTS1077) to the centrifuge tube, and use a disposable sterile dropper to take the diluted peripheral blood and carefully superimpose it on the surface of the separation solution along the tube wall, taking care to maintain a clear interface.

[0129] (4) After completing step (3), place the centrifuge tube in a centrifuge, adjust the speed of increase and decrease to the minimum, and centrifuge at 800g for 20 minutes.

[0130] (5) After completing step (4), the tube is divided into four layers from top to bottom, the first layer is plasma and PBS, the second layer is a ring-shaped milky white lymphocyte layer, the third layer is a transparent separation liquid layer, and the fourth layer is a red blood cell and granulocyte layer. Carefully pipette the second layer of ring-shaped milky white lymphocyte layer into a sterile centrifuge tube (specification: 50 mL), add 40 mL of PBS buffer to the centrifuge tube, mix the cells, centrifuge at 800 g for 5 min, discard the supernatant, and then resuspend the cells in 1640 culture medium, count and set aside to obtain human peripheral T lymphocytes.

[0131] 3. Activation of human peripheral T lymphocytes

[0132] (1) Take a 24-well plate and add 500 μL of anti-CD3 antibody dilution and 500 μL of anti-CD28 antibody dilution to each well. Coat the plate overnight at 4°C.

[0133] Anti-CD3 antibody diluent: dilute anti-CD3 antibody (BioXcell, clone number: OKT3) with PBS buffer to a concentration of 3 μg / mL.

[0134] Anti-CD28 antibody diluent: dilute the anti-CD28 antibody (BioXcell, clone number: CD28.2) with PBS buffer to a concentration of 1 μg / mL.

[0135] (2) After completing step (1), take the 24-well plate, remove the liquid, and wash once with PBS buffer.

[0136] (3) After completing step (2), take the 24-well plate, add 500 μL of human peripheral T lymphocyte dilution solution, and culture at 37° C. for 48 h; then centrifuge at 400 g for 5 min, collect the precipitate and resuspend it in 1640 culture medium to obtain activated human peripheral T lymphocytes.

[0137] Human peripheral T lymphocyte diluent: dilute the human peripheral T lymphocytes obtained in step 2 to 4×10 6 / mL was obtained.

[0138] 4. Preparation of mRNA and electroporation of human peripheral T lymphocytes

[0139] (1) The TCR DNA fragment shown in SEQ ID No. 5 is inserted into a vector as a template for transcription reaction, and then purified with lithium chloride to obtain the corresponding mRNA. The sequence of the obtained mRNA is the sequence obtained by replacing T in SEQ ID No. 5 with U. The mRNA can be obtained by a common mRNA transcription method or by artificial synthesis.

[0140] (2) Activated human peripheral T lymphocytes were cultured until they were in good condition and 1×10 7 The ratio of cells was calculated, and an appropriate amount of T cell suspension was taken and centrifuged at 1300rpm for 5min. The supernatant was discarded, and then the T cells were washed 1-2 times with Opti-MEM medium without phenol red preheated at 37℃, and centrifuged at 1300rpm for 5min. Each sample was resuspended with 100μL Opti-MEM medium, and then 20μg mRNA was taken from each sample and mixed evenly with the T cell suspension, and quickly transferred to the electroporation cup to ensure that no bubbles were generated, and then electroporation was immediately performed, 200V 800Us 1000ms electric shock 3 times, and then the electroporation cup was placed in a 37℃ incubator for incubation for 20min. The electroporation cup was rinsed 1-2 times with 1640 medium (rhIL2), and the cell suspension was transferred to a 6-well plate for culture, and the expression of the corresponding gene was detected within 48h.

[0141] T cells without mRNA transfection were used as negative control.

[0142] (3) TCR expression detection after electroporation Figure 4 The results showed that the T cells after mRNA transfer successfully expressed the target TCR.

[0143] 5. Human TCR-T has the function of killing target cells in vitro

[0144] Substrate, stop solution and cell lysis solution were all from CytoTox Components of the Non-Radioactive Cytotoxicity Assay Kit (Promega, Cat. No. G1780).

[0145] (1) Digestion and counting of 293T cells stably transfected with HLA-A11. These cells can stably express HLA-A11 and present the acute myeloid leukemia-specific antigen-associated peptide DNMT3A-R882S, and can be used as target cells for killing experiments.

[0146] The 293T cells stably transfected with HLA-A11 were maintained by the laboratory and recorded in the literature (The splicing isoformFoxp3Δ2differentially regulates tTreg and pTreg homeostasis. Cell reports. 2023; 42(8): 112877).

[0147] (2) The target cells obtained in step (1) were added to a 96-well plate (2×10 4 / well; then human TCR-T cells (i.e., the mRNA-transfected T cells obtained in step 4) were added at an effector-target ratio of 10:1, 5:1 or 1:1, and 10 mg / ml of DNMT3A-R882S polypeptide (whose sequence is SEQ ID No. 7 in the sequence table) was added to the experimental group, and cultured at 37°C, 5% CO2 for 4 hours.

[0148] (3) Take the 96-well plate that has completed step (2), centrifuge at 250g for 4 minutes, then transfer 50 μL of the supernatant to a new 96-well plate, add 50 μL of substrate to each well, and incubate at room temperature in the dark for 30 minutes; then add 50 μL of stop solution to each well, and use a microplate reader (wavelength 490 nm) to read the value, which is the value of the experimental group.

[0149] (4) Background value detection of killing experiment

[0150] ① According to the above steps (1)-(3), replace step (2) with step (2A), and keep the other steps unchanged. The value read by the microplate reader is the T cell self-release value. Step (2A): Take a 96-well plate, add the same number of Human TCR-T cells as the experimental group, and culture at 37°C and 5% CO2 for 4 hours.

[0151] ② According to the above steps (1)-(3), replace step (2) with step (2B), and keep the other steps unchanged. The value read by the microplate reader is the target cell self-release value. Step (2B): Take a 96-well plate, add the same number of target cells as the experimental group, and culture at 37°C and 5% CO2 for 4 hours.

[0152] ③ According to the above steps (1)-(3), replace step (2) with step (2C), and keep the other steps unchanged. The value read by the microplate reader is the maximum release value of the target cells. Step (2C): Take a 96-well plate, add the same number of target cells as the experimental group and 10 μL of cell lysis solution, and culture at 37°C, 5% CO2 for 4 hours.

[0153] 6. Calculate the killing activity

[0154] Killing activity = (experimental group value - T cell self-release value - target cell self-release value) / (target cell maximum release value - target cell self-release value) × 100%.

[0155] The Human TCR-T in the above method was replaced with Human T cells without TCR transfection, and other steps remained unchanged as a control.

[0156] The results of the in vitro killing of target cells by Human TCR-T cells are shown in Figure 5 The results showed that Human TCR-T cells can effectively kill target cells in vitro.

[0157] 7. Detection of cytokine release

[0158] The ratio of effector cells to target cells in step 5 was adjusted to 1:1, and the target cells were 2×10 4 pcs / well were added to a 96-well plate, and Monensin was added to the cells to block the Golgi apparatus from transporting proteins to the extracellular space; at the same time, 10 mg / ml of DNMT3A-R882S polypeptide was added to the experimental group, and no polypeptide was added to the control group culture system.

[0159] The cells were cultured at 37°C and 5% CO2 for 4 h, and then flow cytometry intracellular staining was used to detect the secretion of cytokines IFN-γ and TNF-α.

[0160] Results Figure 6 When stimulated by specific peptide antigens, TCR-transduced human T cells significantly increase the secretion of cytotoxic cytokines IFN-γ and TNF-α.

[0161] In summary, the inventors of the present invention separated and identified a pair of DNMT3A-R882S-specific TCR sequences, successfully constructed corresponding TCR-T cells, and determined that this pair of TCR sequences specifically recognized and bound the DNMT3A-R882S epitope peptide / HLA-A11 complex; at the same time, TCR transgenic positive human CD8 cells (TCR-T) have DNMT3A-R882S epitope peptide-dependent killing target cells and can release effector cytokines. The T cell receptor for the HLA-A11-restricted DNMT3A-R882S epitope peptide provided by the present invention has important application value.

[0162] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A T cell receptor comprising an α chain and a β chain, wherein the α chain comprises complementary determining regions CDR1α, CDR2α and CDR3α, and CDR1α is a1) or a2): a1) the polypeptide shown at positions 47 to 52 of SEQ ID No. 2; a2) a T cell receptor alpha chain complementary determining region having more than 75% identity with a1) obtained by substitution and / or deletion and / or addition of one or more amino acid residues; CDR2α is a3) or a4): a3) the polypeptide shown at positions 70-75 of SEQ ID No.2; a4) a T cell receptor alpha chain complementary determining region having more than 75% identity with a3) obtained by substituting and / or deleting and / or adding one or more amino acid residues in a3); CDR3α is a5) or a6): a5) the polypeptide shown at positions 110-118 of SEQ ID No. 2; a6) a T cell receptor alpha chain complementary determining region having more than 75% identity with a5) obtained by substituting and / or deleting and / or adding one or more amino acid residues in a5); The β chain contains complementarity determining regions CDR1β, CDR2β and CDR3β, and CDR1β is b1) or b2): b1) the polypeptide shown at positions 46 to 50 of SEQ ID No. 4; b2) a T cell receptor alpha chain complementary determining region having more than 75% identity with b1) obtained by substituting and / or deleting and / or adding one or more amino acid residues of b1); CDR2β is b3) or b4): b3) the polypeptide shown at positions 68-73 of SEQ ID No. 4; b4) a T cell receptor alpha chain complementary determining region having more than 75% identity with b3) obtained by substituting and / or deleting and / or adding one or more amino acid residues of b3); CDR3β is b5) or b6): b5) the polypeptide shown at positions 111-122 of SEQ ID No. 4; b6) a T cell receptor α chain complementary determining region having more than 75% identity with b5) obtained by substituting and / or deleting and / or adding one or more amino acid residues in b5).

2. The T cell receptor according to claim 1, Features: The variable region of the α chain is a7) or a8): a7) the polypeptide shown at positions 21 to 110 of SEQ ID No. 2; a8) a variable region of a T cell receptor alpha chain having more than 75% identity with a7) obtained by substituting and / or deleting and / or adding one or more amino acid residues in a7); The variable region of the β chain is b7) or b8): b7) shown in positions 20-114 of SEQ ID No. 4; b8) A T cell receptor α chain variable region having more than 75% identity with b7) obtained by substituting and / or deleting and / or adding one or more amino acid residues in b7).

3. The T cell receptor according to claim 1 or 2, Features: The α chain and the β chain comprise the constant region of a murine, human or humanized T cell receptor.

4. The T cell receptor according to claim 3, Features: The α chain is a9) or a10): a9) the polypeptide shown in SEQ ID No.2; a10) a T cell receptor α chain having more than 75% identity with a9) obtained by substituting and / or deleting and / or adding one or more amino acid residues; The beta chain is b9) or b10): b9) the polypeptide shown in SEQ ID No.4; b10) A T cell receptor β chain having more than 75% identity with b9) obtained by substituting and / or deleting and / or adding one or more amino acid residues in b9).

5. The biological material associated with the T cell receptor according to any one of claims 1 to 4, which is any one of the following C1) to C5): C1) a nucleic acid molecule encoding the T cell receptor according to any one of claims 1 to 4; C2) an expression cassette containing the nucleic acid molecule described in C1); C3) a recombinant vector containing the nucleic acid molecule described in C1), or a recombinant vector containing the expression cassette described in C2); C4) a recombinant microorganism containing the nucleic acid molecule described in C1), or a recombinant microorganism containing the expression cassette described in C2), or a recombinant microorganism containing the recombinant vector described in C3); C5) A cell, tissue or organ containing the nucleic acid molecule described in C1), or a cell, tissue or organ containing the expression cassette described in C2).

6. The biomaterial according to claim 5, Features: C1) The nucleic acid molecule is a nucleic acid molecule encoding the α chain and the β chain according to any one of claims 1 to 4.

7. The biomaterial according to claim 5 or 6, Features: In the α chain, the nucleic acid molecule encoding CDR1α is the DNA molecule shown at positions 139-156 of SEQ ID No.1, the nucleic acid molecule encoding CDR2α is the DNA molecule shown at positions 208-225 of SEQ ID No.1, and the nucleic acid molecule encoding CDR3α is the DNA molecule shown at positions 328-354 of SEQ ID No.1; Further, the nucleic acid molecule encoding the variable region of the α chain is the DNA molecule shown at positions 61-330 of SEQ ID No.1; Furthermore, the nucleic acid molecule encoding the α chain is a DNA molecule shown in SEQ ID No. 1; In the β chain, the nucleic acid molecule encoding CDR1β is the DNA molecule shown at positions 136-150 of SEQ ID No.3, the nucleic acid molecule encoding CDR2β is the DNA molecule shown at positions 202-219 of SEQ ID No.3, and the nucleic acid molecule encoding CDR3β is the DNA molecule shown at positions 331-366 of SEQ ID No.3; Further, the nucleic acid molecule encoding the variable region of the β chain is the DNA molecule shown at positions 58-342 of SEQ ID No.3; Furthermore, the nucleic acid molecule encoding the β chain is a DNA molecule shown in SEQ ID No.

3.

8. A pharmaceutical composition comprising the T cell receptor according to any one of claims 1 to 4, or the biomaterial according to any one of claims 5 to 7.

9. The pharmaceutical composition according to claim 8, Features: The pharmaceutical composition also contains a DNMT3A-R882S polypeptide.

10. Any of the following uses of the T cell receptor according to any one of claims 1 to 4, or the biomaterial according to any one of claims 5 to 7, or the pharmaceutical composition according to claim 8 or 9: X1) treatment and / or prevention of blood disorders; X2) preparation of products for the treatment and / or prevention of blood disorders; X3) Treatment and / or prevention of acute leukemia; X4) Preparation of products for the treatment and / or prevention of acute leukemia; X5) Treatment and / or prevention of acute myeloid leukemia; X6) Preparation of products for the treatment and / or prevention of acute myeloid leukemia; X7) treating and / or preventing diseases caused by the R882S mutation of DNMT3A; X8) Prepare products for treating and / or preventing diseases caused by the R882S mutation of DNMT3A. X9) treating and / or preventing DNMT3A-R882S-positive acute myeloid leukemia; X10) preparing a product for treating and / or preventing DNMT3A-R882S-positive acute myeloid leukemia; X11) killing target cells expressing DNMT3A-R882S epitope peptide in vivo or in vitro; X12) preparing products for killing target cells in vivo or in vitro; X13) Elimination of DNMT3A-R882S positive cells; X14) preparing a product for eliminating DNMT3A-R882S positive cells; X15) preparing cytotoxic cytokines IFN-γ and / or TNF-α.

11. Application of DNMT3A-R882S polypeptide in the preparation of T cell receptors for acute myeloid leukemia epitope peptides.

Citation Information

Patent Citations

  • Method, primer and kit for detecting DNMT3A mutation site

    CN103540659A

  • Shared neoantigens

    CN108025048A

  • Methods of determining risk of adverse outcomes in acute myeloid leukemia

    WO2012078288A2